Skip to content
Action Kidney Cancer Logo Action Kidney Cancer Logo
  • Home
  • About us
  • Contact us
  • Help & support
  • Kidney cancer
  • Research
  • Get involved
  • Downloads
  • Home
  • About us
  • Contact us
  • Help & support
  • Kidney cancer
  • Research
  • Get involved
  • Downloads
Helpline
0800 121 8721
Email us
Donate

Neutrophil-eosinophil ratio predicts response of kidney cancer to ipilimumab plus nivolumab

Home/Drug treatments/Neutrophil-eosinophil ratio predicts response of kidney cancer to ipilimumab plus nivolumab

Neutrophil-eosinophil ratio predicts response of kidney cancer to ipilimumab plus nivolumab

31 Aug 2022

Tags
biomarkers combination therapy immunotherapy ipilimumab neutrophil-eosinophil ratio nivolumab renal cell carcinoma
  • View Larger Image
Listen to this News
Print this News

Share this Page:

FacebookTwitterLinkedInWhatsAppTumblrPinterestVkXingEmail

Neutrophils and eosinophils are white blood cells. In this study, 166 patients with kidney cancer that had spread to other organs and other parts of the body (metastatic kidney cancer) were treated with a combination of ipilimumab and nivolumab. The researchers were looking for a link between the ratio of neutrophils to eosinophils with patient outcomes.

Most patients had low or intermediate risk kidney cancer – only 15% had high risk disease. Two thirds had had surgery, and one third had been treated with medicine before entering the study. Patients were followed for nearly a year.

The average neutrophil to eosinophil ratio was lower in patients who responded to treatment 12 weeks after the start of the study. The biggest difference in neutrophil to eosinophil ratio was seen at 6 weeks. A decrease in the neutrophil to eosinophil ratio was associated with improved survival in patients treated with the ipilimumab plus nivolumab combination. A low baseline neutrophil to eosinophil ratio was associated with favourable survival and response to treatment.

This study shows that a decrease in the ratio of neutrophil to eosinophil white blood cells 6 weeks after the start of treatment can be an early predictive biomarker of future response to the ipilimumab plus nivolumab combination. Further studies are needed to confirm these findings and to see if the same is true for other immunotherapy-based combinations.

Read more in the journal Cancers here

Listen to this News
Print this News

Share this Page:

FacebookTwitterLinkedInWhatsAppTumblrPinterestVkXingEmail

Kidney cancer news

24 Jan 2023

Pembrolizumab plus axitinib for metastatic papillary and chromophobe kidney cancer

Read More

17 Jan 2023

Real-world survival outcomes of metastatic papillary and clear cell kidney cancer

Read More

12 Jan 2023

Long-term data support first-line use of avelumab and axitinib for advanced kidney cancer

Read More

12 Jan 2023

Does neoadjuvant therapy improve outcomes in localised kidney cancer?

Read More

6 Jan 2023

BioNTech forms alliance with UK government for cancer immunotherapies

Read More

3 Jan 2023

CA-125 biomarker for renal medullary carcinoma

Read More

16 Dec 2022

Shared decision-making in kidney cancer

Read More

15 Dec 2022

Long term outcomes after SABR for kidney cancer tumours

Read More

12 Dec 2022

New method enables early detection of cancer

Read More

7 Dec 2022

Psychological distress in patients treated for kidney cancer

Read More

6 Dec 2022

BMI and outcomes in patients with metastatic kidney cancer treated with first-line TKIs

Read More

30 Nov 2022

NICE approves pembrolizumab plus lenvatinib combination for advanced kidney cancer

Read More

Most used tags

renal cell carcinoma immunotherapy checkpoint inhibitors combination therapy Cancer TKIs overall survival nivolumab Opdivo sunitinib Sutent progression-free survival cabozantinib biomarkers NHS England Cabometyx ipilimumab COVID-19 axitinib pembrolizumab cancer survival VEGF inhibitors non-clear cell kidney cancer Inlyta coronavirus Yervoy Keytruda risk factors metastases biological markers adjuvant therapy everolimus targeted therapy papillary RCC Afinitor ASCO cancer outcomes first-line treatment NICE partial nephrectomy

Archives

  • 2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • About kidney cancer
  • Kidney cancer news
  • Kidney cancer treatments
  • Newsletter
  • Glossary
  • Useful links

Address

Action Kidney Cancer

11th Floor
3 Piccadilly Place
Manchester M1 3BN

Helpline

0800 121 8721
Email Us

About Action Kidney Cancer

We are the UK’s largest and most active patient-led kidney cancer charity. Whether you are a patient, survivor or someone you know has been diagnosed with kidney cancer, you have come to the right place to find support and information, and to be part of a caring and knowledgeable community of people: We are here to help you.
Registered charity in England, Wales (1164238), and Scotland (SC051330).
© Copyright Action Kidney Cancer 2021

Links

Home

About us

Donate

Contact us

Our partners

Branding by Kingswood Marketing

Policies

Website Policies

Complaints Policy

Equal Opportunities Policy

Information Governance Policy

Social Media Policy

Follow

Web Design by Douglass Digital

Helpline: 0800 121 8721

support@actionkidneycancer.org

Go to Top